Back to today’s briefing

Story perspectives

Study Reveals Risks of Liraglutide: Muscle Loss and Weight Regain

9/26/2025

48 9

Summary

Story summary

A 2024 study found 60% of weight loss on Liraglutide is lean muscle, reducing function.
Stopping Glucagon-like peptide-1 (GLP-1) agonists often yields weight regain, with two-thirds returned within a year.
GLP-1 therapies can cause pancreatitis, thyroid tumors, and GI issues; 10,000 serious reactions since 2018.
Health Utah uses non-invasive scans and a questionnaire; a British study prompted a promotional package.

1 of 1

Story summary

A 2024 study found 60% of weight loss on Liraglutide is lean muscle, reducing function.
Stopping Glucagon-like peptide-1 (GLP-1) agonists often yields weight regain, with two-thirds returned within a year.
GLP-1 therapies can cause pancreatitis, thyroid tumors, and GI issues; 10,000 serious reactions since 2018.
Health Utah uses non-invasive scans and a questionnaire; a British study prompted a promotional package.